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Abstract
AIM
To determine whether infection in patients with acute 
severe alcoholic hepatitis (AAH) treated with corti-
costeroids is associated with increased mortality.
METHODS
Consecutive patients with AAH were treated with 
steroids and recruited to the study. Clinically relevant 
infections (body temperature > 38 ℃ or < 36 ℃ for 
more than 4 h, ascitic neutrophil count > 0.25 ×
109/L, consolidation on chest radiograph or clinically 
relevant positive microbiological culture of bodily fluid) 
were recorded prospectively. Clinical and laboratory 
parameters were recorded and survival at 90 d and 
6 mo was determined. Univariate analysis of factors 
associated with 90-d mortality was performed and 
significant variables included in a multivariate analysis.
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RESULTS
Seventy-two patients were included in the final analysis 
(mean age 47.9 years, 26% female, mean discriminant 
function 53.0). Overall mortality in the group occurred 
in 15 (21%), 23 (32%) and 31 (43%) at day 28, day 
90 and 1 year respectively. 36 (50%) had a clinically 
relevant infection during their hospitalisation (23 after 
initiation of steroids). The median time to development 
of incident infection after commencement of steroids 
was 10 d. The commonest site of infection was ascites 
(31%) and bacteraemia (31%) followed by urinary 
tract (19%) and respiratory tract (8%). Forty-one 
separate organisms were isolated in 33 patients; the 
most frequent genus was Escherichia (22%) and 
Enterococcus (20%). Infection was not associated 
with 90-d or 1 year mortality but was associated with 
higher creatinine, model for end-stage liver disease 
and Lille score. Baseline urea was the only independent 
predictor of 90-d mortality.
CONCLUSION
Clinically relevant infections are common in patients 
with AAH but are not associated with increased 90-d or 
1 year mortality.
Key words: Alcoholic hepatitis; Escherichia; Infection; 
Lille score; Corticosteroids
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Core tip: Corticosteroids are the only treatment shown 
to improve outcome in patients with acute severe 
alcoholic hepatitis (AAH) but may be associated 
with increased rates of infection and mortality. In 
this prospective cohort study of patients with AAH 
treated with corticosteroids rates of clinically relevant 
infections were accurately documented. Half of the 
study participants developed an infection during their 
hospitalisation with the commonest sites being ascites 
and bacteraemia. Infection was associated with higher 
creatinine, model for end-stage liver disease and lille 
score but not with higher 90-d or 1 year mortality. 
Infection is common in patients with AAH but is not 
associated with increased mortality.
Dhanda AD, Sinha A, Hunt V, Saleem S, Cramp ME, Collins 
PL. Infection does not increase long-term mortality in patients 
with acute severe alcoholic hepatitis treated with corticosteroids. 




Alcoholic hepatitis is an acute syndrome characte­
rised by recent onset jaundice and coagulopathy in a 
patient with a history of prolonged and heavy alcohol 
consumption[1]. Despite improved recognition of and 
research interest in the condition, mortality remains 
high in patients with acute severe alcoholic hepatitis 
(AAH; traditionally defined as having a discriminant 
function > 32[2]) with 90 d and 1 year mortality of 
29% and 56% respectively[3]. Data regarding cause of 
death is challenging to capture but a Danish registry 
study suggests that early mortality (within 84 d) is 
mostly liver related (58%) or due to infection (20%) 
while late mortality is also contributed to by cancer 
and alcohol and 16% is still due to infection[4]. Other 
than abstinence from alcohol the only treatment with 
a proven short-term survival benefit is corticosteroids 
(steroids)[5]. However, this benefit may be outweighed 
by the increased risk of infection posed by steroid 
treatment. Although some randomised controlled trials 
(RCTs) have reported higher rates of infection in steroid 
treated patients[3,6], it remains controversial whether 
increased infections result in increased mortality.
Increased risk of mortality was clearly described 
in a prospective cohort study in which infections that 
developed after initiation of steroid treatment were 
associated with increased 2 mo mortality[7]. However, 
adequately treated infections prior to commence­
ment of steroids were not associated with increased 
mortality risk. A retrospective cohort analysis also 
demonstrated that infection at presentation or during 
hospitalisation was associated with increased 1 year 
mortality risk on univariate but not multivariate 
analysis[8]. However, only 43% of the cohort received 
steroids and the interaction between steroids and 
infection was not investigated. A recent sub­analysis 
from the United Kingdom STOPAH trial data found that 
prednisolone treatment was associated with increased 
risk of infection in the post­treatment period and that 
incident infection increased 28­ and 120­d mortality 
but this was independent of steroid treatment[9]. A 
meta­analysis of data from 12 RCTs including a steroid 
arm did not demonstrate any increased infection or 
mortality risk associated with steroids except with the 
occurrence of fungal infections, which were uncommon 
(9 out of 1062 patients)[10].
The inconsistency of these data may be explained 
by poor recording of infections in clinical trials (which 
do not always specify prospective collection of infection 
information) and due to insufficient detail in retrospective 
analyses. Here, we add to the existing literature with a 
single centre prospective cohort of patients with AAH 
including long­term follow­up data.
MATERIALS AND METHODS
This study was conducted in accordance with the 
principles of the Declaration of Helsinki and was 
approved by the NHS Health Research Authority (07/
Q2007/09). Written informed consent was obtained 
from participants or, where they lacked capacity, assent 
was obtained from a personal or nominated consultee.
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Consecutive patients admitted to University Hos­
pitals Bristol NHS Foundation Trust with AAH from 
October 2007 to September 2015 were prospectively 
recruited to this study. AAH was defined as new 
onset jaundice (within the previous 3 mo) with serum 
bilirubin > 80 µmol/L and coagulopathy in a heavy 
drinker [more than 10 units alcohol (80 g ethanol) 
daily in males and 7.5 units (60 g ethanol) in females 
within the previous 4 wk]. Additionally, discriminant 
function[2] was greater than 32.
Clinically relevant infections were recorded at first 
presentation and prospectively during hospital ad­
mission and were defined as a body temperature > 
38 ℃ or < 36 ℃ for more than 4 h, ascitic neutrophil 
count > 0.25 × 109/L, consolidation on chest radiograph 
or clinically relevant positive microbiological culture of 
bodily fluid.
All patients were screened for infection on ad­
mission to hospital with chest radiograph, urinalysis, 
ascitic fluid analysis (where ascites was present) and 
peripheral blood cultures if body temperature was 
greater than 38 ℃. In patients with temperature < 
38 ℃ and negative infection screen, oral prednisolone 
was commenced at a dose of 40 mg daily and con­
tinued for 28 d. Patients with a positive infection 
screen or body temperature > 38 ℃ were treated with 
broad spectrum intravenous antibiotics according to 
Trust protocol for at least 48 h before converting to 
oral antibiotics. In these patients the 28 d course of 
prednisolone was only started after temperature < 
38 ℃ had been recorded for at least 48 h.
Patients who developed clinically relevant infection 
after initiation of steroid treatment (incident infec­
tions) were treated within 12 h with intravenous broad 
spectrum antibiotics according to Trust protocol for at 
least 48 h before being converted to oral antibiotics. 
Steroids were not discontinued during or after incident 
infections except in those in whom active treatment 
was withdrawn and palliative care was initiated.
Routine laboratory data were collected at baseline, 
day 7 and 28 of steroid treatment and survival status 
was recorded at day 90, 6 and 12 mo. Survival was 
determined by accessing Trust databases which are 
linked to community databases and where necessary 
by direct contact with the patient’s General Practitioner. 
Alcohol consumption at follow­up was determined by 
face­to­face or telephone consultations carried out 
by the Alcohol Liaison Team at regular intervals after 
hospital discharge.
Patients who did not receive prednisolone or in 
whom investigators were blinded to their treatment 
(where they also participated in the United Kingdom 
STOPAH clinical trial) were excluded from this analysis.
Statistical analysis
Patient characteristics, baseline laboratory parameters, 
day 7 serum bilirubin levels and composite scores 
[discriminant function (DF), Glasgow Alcoholic Hepatitis 
Score (GAHS), Model for End­stage Liver Disease 
(MELD) and Lille score[11]] were compared between 
survivors and non­survivors at day 90 by univariate 
analysis with Mann­Whitney U tests for continuous 
data and Fisher Exact tests for categorical data. Terms 
that were found to be significant at the 5% level 
of significance were then included in a multivariate 
regression model which used survival at day 90 as the 
dependent variable. 
Kaplan­Meier survival analysis was also performed 
at day 90 and 1 year. Survival was compared between 
patients with clinically relevant infection on admission, 
post­steroid initiation and at any time by log­rank test.
RESULTS
A total of 116 participants were recruited to the 
study; 44 were excluded as treatment allocation was 
blinded due to participation in the STOPAH trial (n = 
42) or they did not receive prednisolone (n = 2; 1 
with concurrent active hepatitis C infection and 1 with 
a borderline DF which improved to less than 32 in 
24 h without treatment). Therefore 72 patients were 
included in the final analysis (mean age 47.9 years, 
26% female, mean DF 53.0; Table 1). Overall mortality 
in the group occurred in 15 (21%), 23 (32%) and 31 
(43%) at day 28, day 90 and 1 year respectively.
During the period of recruitment to the STOPAH 
trial in our centre (April 2011 to December 2013), 27 
patients who met the STOPAH trial selection criteria 
were not recruited to it either due to patient choice or 
because steroids were commenced prior to screening 
and were hence included in the present study. These 
patients represent a similar population to the study 
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Table 1  Patient characteristics at baseline (day 0 of steroid 
treatment) and day 7 of steroid treatment (n  = 72) and 
survival at day 28, day 90 and 12 mo
Age   47.9 ± 10.6
Male (%) 74
Baseline CRP (mg/L)      33 ± 26.8
Baseline bilirubin (µmol/L)   294 ± 142
Baseline albumin (g/L)    25 ± 7.7
Baseline INR   1.9 ± 0.5
Baseline PT (s) 19.2 ± 4.6
Baseline urea (µmol/L)   3.9 ± 2.7
Baseline creatinine (µmol/L)      90 ± 56.6
Baseline WBC (× 109/L)   9.1 ± 4.5
Day 7 bilirubin (µmol/L)   251 ± 174
Baseline DF   53.0 ± 24.4
Baseline GAHS   8.1 ± 1.4
Baseline MELD 22.3 ± 6.7
Lille score   0.403 ± 0.350
Day 28 survival (%) 21
Day 90 survival (%) 32
12 mo survival (%) 43
CRP: C-reactive protein; INR: International normalised ratio; PT: 
Prothrombin time; WBC: White blood count; DF: Discriminant function; 
GAHS: Glasgow alcoholic hepatitis score; MELD: Model for end-stage 
liver disease.
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In those that developed incident infections after 
initiation of steroids there were 9 cases of SBP, 4 
urinary tract infections, 2 respiratory infections, 5 
bacteraemias and 5 infections at other sites (2 ear 
infections, 2 GI tract infections and 1 cellulitis). A 
source of infection was not determined in 2 patients. 
Four of these patients had non­concurrent infections at 
more than one site.
Overall bacteraemia and SBP were the most 
common sites of infection (11 each) followed by 
urinary tract (7) and respiratory tract (3; Figure 
1A and Supplementary Table). The median time to 
commencement of steroids from hospital admission 
was 2 d (mean 2.4 d) in all patients. In those with 
infection identified at the time of admission the median 
time to commencement of steroids was 3 d (mean 5.0). 
The median time to the first incident infection after 
commencement of steroids was 10 d (range 2­42 d).
Commonest causative organisms are catalase positive
The causative bacterial genus was isolated from 41 
separate clinically relevant infections in 33 individual 
patients. The commonest genus was Escherichia (9; 
22%) followed by Enterococcus (8, 20%), Streptococcus 
(5; 12%) and Staphylococcus, Pseudomonas and 
Micrococcus (4 each; 10%; Figure 1B). Seven patients 
had non­concurrent infections with more than 1 or­
ganism and in 3 patients 2 organisms were identified 
participants recruited outside the STOPAH trial recruit­
ment period in terms of age (49 vs 47, P = 0.87), 
gender (26% vs 27% female, P = 1.0) and disease 
severity (DF 53.7 vs 52.7, P = 0.46). Additionally, 
there were no statistical differences between patients 
in the current study and those recruited to the STOPAH 
clinical trial from our centre (n = 42). Age was similar 
(48 vs 51, P = 0.14) as was DF (53.0 vs 53.1, P = 0.88), 
90 d mortality (23% vs 32%, P = 0.48) and 1 year 
mortality (43% vs 42%, P = 1.0).
Clinically relevant infections occur in half of patients 
with AAH
In total 36 patients (50%) had a clinically relevant 
infection during their hospital stay with 8 (11%) on 
admission, 7 (10%) prior to initiation of steroids 
and 23 (32%) after initiation of steroids (including 2 
who also had a separate infection on admission). On 
admission, bacteraemia was present in 3 patients (all 
Escherichia coli), spontaneous bacterial peritonitis 
(SBP) in 2, respiratory infection in 1 and urinary tract 
infection and SBP in 1. No obvious source of infection 
could be identified in 1 patient.
Of the 7 patients who developed a clinically relevant 
infection after admission but prior to initiation of steroids 
3 were due to bacteraemia, 2 urinary tract infections, 1 
gastrointestinal (GI) infection and 1 in whom no proven 

















Figure 1  Site and causative bacterial genus of all clinically relevant infections during hospital admission for acute severe alcoholic hepatitis. A: The site 
of clinically relevant infections (n = 36). The “Other” category includes gastrointestinal tract and cutaneous; B: The causative bacterial genus where identified by 
microbiological analysis in 41 separate clinically relevant infections. The “Other Genus” group includes Acinebacter (n = 2), Haemophilus (n = 1), Clostridium difficile (n 
= 2) and norovirus (n = 1); C: Catalase status of identified bacteria (n = 40).
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from the same specimen. Four other infective organisms 
were identified: Acinetobacter (2 cases), Clostridium 
difficile (2 cases), Haemophilus and norovirus. Of the 
36 patients with clinically relevant infections, 23 (64%) 
had infections with catalase positive bacteria including 2 
patients who had infections with both catalase negative 
and positive organisms (Figure 1C).
Clinically relevant infection is associated with high Lille 
score
Clinically relevant infection was not significantly 
associated with biochemical or haematological markers 
of infection at baseline or day 7 of steroid treatment: 
baseline C­reactive protein was 36 vs 30 g/L (P = 0.40), 
baseline white blood count (WBC) was 9.9 vs 8.3 × 
109/L (P = 0.14) and day 7 WBC was 13.4 x109/L vs 
10.5 × 109/L (P = 0.08) in patients with infection vs no 
infection respectively. However, presence of clinically 
relevant infection was associated with higher creatinine 
(105 vs 73 µmol/L, P = 0.01), MELD (23.9 vs 20.6, P 
= 0.04) and Lille score (0.51 vs 0.28, P = 0.01) than 
those without infection.
Urea is the only independent predictor of 90 d survival
Univariate analysis of patient characteristics, baseline 
and day 7 biochemistry and composite scores identified 
age, baseline urea and baseline GAHS as significantly 
different between survivors and non­survivors at day 
90 (Table 2). GAHS was excluded from multivariate 
analysis due to co­linearity with the other variables. 
Applying age and urea to a multivariate regression 
model identified only urea as an independent predictor 
of 90­d outcome (P = 0.01; Table 3 and Supplementary 
Table).
Infection does not predict short- or long-term survival
In total 11 and 15 out of 36 patients who developed 
infection died at 90 d or 12 mo respectively compared 
to 12 and 16 out of 36 of the patients without infection. 
Kaplan­Meier survival analysis from the time of steroid 
commencement did not demonstrate a significant 
survival difference between groups at any time. The 
same was true in patients with clinically relevant 
infection at the time of hospital admission (P = 0.26 at 
90 d and P = 0.67 at 1 year; no censored data; Figure 
2A and B). There was neither a 90 d nor 1 year survival 
difference in patients with and without an incident 
infection after commencement of steroids (P = 0.78 at 
90 d and P = 0.98 at 1 year; no censored data; Figure 
2C).
DISCUSSION
In this cohort of patients with AAH in which clinically 
relevant infections were clearly defined and docu­
mented prospectively, 50% developed an infection 
during the study period which was not associated with 
increased mortality at 90 d or 1 year. 11% of patients 
presented with clinically relevant infection, 10% 
developed infection after admission but prior to steroid 
initiation and 32% developed an incident infection 
during steroid treatment but the timing of infection 
did not influence survival. In agreement with recently 
published studies, Escherichia and Enterococcus genii 
were the commonest bacterial pathogens isolated[12,13]. 
The commonest site of infection was ascites (31%) 
and 31% had bacterial septicaemia. In only 3 patients 
a site of infection could not be identified.
Although this is a single centre study, the patient 
cohort is representative of United Kingdom patients 
with AAH with study selection criteria similar to the 
recent STOPAH clinical trial[3]. Mean age in this study 
was 47.9 years (in comparison to 48.7 years in 
STOPAH), with 74% male (68% male in STOPAH) and 
mean discriminant function 53.0 (62.6 in STOPAH). 
Mortality is also comparable with the STOPAH study 
and other recent clinical trials with overall mortality 
of 21%, 32% and 43% at day 28, day 90 and 1 year 
respectively[3,6,14,15]. This study has the added advantage 
over multicentre studies of having standardised patient 
management by a small team of clinicians which 
reduces variability in patient outcome.
Data regarding infection in AAH are sparse in the 
literature and of varying quality. Uniquely, this study 
has robustly prospectively recorded clinically relevant 
infections. This is reflected in the higher rate of in­
fections noted here compared to only 13% recorded in 
the prednisolone treated patients in the STOPAH trial, 
which was likely an underestimate of the true rate of 
infection since it relied on clinician judgement to report 
Table 2  Univariate analysis of variables at baseline and day 
7 of steroid treatment to assess association with day 90 
outcome
Day 90 outcome P  value
Survivor 
(n  = 49)
Non-survivor 
(n  = 23)
Age (yr)   45   53 0.01
Gender (% male)   73   74 1.00
Sepsis on admission (%)   10   13 0.50
Sepsis at any time (%)   51   48 1.00
Sepsis after steroids (%)   33   30 1.00
CRP (mg/L)   30   40 0.15
Baseline bilirubin (µmol/L) 301 279 0.52
Baseline albumin (g/L)   25   24 0.38
Baseline INR   1.8     2 0.14
Baseline PT (s) 18.6 20.5 0.17
Baseline urea (µmol/L)   3.2   5.5 < 0.01
Baseline creatinine (µmol/L)   90   91 0.93
Baseline WBC (× 109/L)     9   10 0.44
Day 7 bilirubin (µmol/L) 244 254 0.67
Baseline DF 51.1 57.2 0.41
Baseline GAHS   7.8   8.7 0.04
Baseline MELD 21.7 23.7 0.23
Lille score     0.38     0.46 0.38
Continuous variables were compared by Mann-Whitney U test and 
categorical data by Fisher Exact test. CRP: C-reactive protein; INR: 
International normalised ratio; PT: Prothrombin time; WBC: White blood 
count; DF: Discriminant function; GAHS: Glasgow alcoholic hepatitis 
score; MELD: Model for end-stage liver disease. 
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it as a serious adverse event[3].
A meta-analysis of 12 RCTs with sufficient infection 
data (including the STOPAH study) described incident 
infections occurring in 20% of patients without a higher 
rate in steroid treated patients[10]. The commonest 
infection was sepsis of unknown source followed by 
respiratory tract infections. It concluded that infection 
after steroid commencement was not associated with 
increased mortality at 28 d. However, the effect on 
longer term mortality was not assessed and most of 
the 12 studies were historic from more than 20 years 
ago highlighting the fact that many recent studies 
have not collected high quality data on infections.
A French single centre prospective study of 246 
patients reported infection in 26% at presentation 
and 24% developed an incident infection after 
commencement of steroid treatment[7]. In agreement 
with the current study SBP was once again the com­
monest infection on admission but respiratory tract 
infections were more common in those with incident 
infection. Patients who had an infection at admission 
had a similar outcome to other patients but those 
who developed infection on steroid treatment had a 
reduced 60­d survival. However, they demonstrated 
that the biochemical response to steroids (using 
the Lille score) and not infection itself was the most 
important determinant of survival. A more recent RCT 
also concluded that treatment non­responders rather 
than responders were at higher risk of death from 
infection (14% vs 4%[6]). In the present study, clinically 
Table 3  Multivariate regression analysis with 90 d outcome as the dependent variable and age and baseline urea as independent 
variables 
R 2 Adjusted R 2 B Std. Error F Sig
Model 0.205 0.182 0.425 8.87 < 0.001
Constant -0.351 0.234 0.138
Urea  0.054 0.020 0.010
Age  0.010 0.005 0.071
The model generated accounted for approximately 20% of the dependent variable (R2 = 0.205). The model demonstrated that urea was the only statistically 
significant predictor of 90 d outcome.
Dhanda AD et al . Infection in alcoholic hepatitis
Figure 2  Clinically relevant infection does not significantly affect early or late mortality. Kaplan-Meier survival curves of AAH patients with (n = 9) and without (n 
= 63) clinically relevant infection at the time of hospital admission at 90 d (A) and 1 year (B); P = 0.26 and P = 0.67 respectively; C: One year survival of AAH patients 
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relevant infection at any time during hospital admission 
was associated with a significantly higher Lille score. 
Conversely, Lille non­responders (Lille score > 0.45) 
had a trend to increased rates of clinically relevant 
incident infection (48% vs 24%, P = 0.07) but the 
Lille score itself was not identified as an independent 
predictor of outcome. These data suggest there is an 
interaction between biochemical response to treatment 
and infection which influences survival. However, it 
cannot be determined whether infection itself has an 
effect on liver biochemistry or whether treatment non­
response increases susceptibility to infection.
An increased infection rate is seen in patients with 
AAH due to generalised immune dysfunction. Recent 
studies have investigated the immune defect in more 
detail and describe impaired monocyte oxidative 
burst, phagocytic capacity as well as increased T 
cell exhaustion[12,16]. The current data support these 
findings since the majority of bacterial isolates were 
able to produce catalase which is protective against 
phagocytic oxidative burst. Interestingly these effects 
were independent of steroid treatment[12] suggesting 
that steroids do not increase susceptibility to infection 
through this mechanism.
Local clinical protocols in our liver unit mean all 
patients with clinically relevant infection are treated 
rapidly (within 12 h) after first identification of infection. 
Additionally, in those presenting with infection, steroids 
were withheld until at least 48 h of intravenous broad 
spectrum antibiotics had been received and they were 
free from clinical signs of infection for this period. This 
protocol was adhered to in all patients in this study. This 
proactive antibiotic treatment policy may partly explain 
why no increased risk of mortality is associated with 
infection in these patients with AAH.
This prospective observational cohort study demon­
strates that clinically relevant infections that are sought 
and treated early with broad spectrum antibiotics do 
not influence short- or long-term mortality in patients 
with severe AAH treated with steroids. However, long­
term mortality of patients with AAH remains high 
primarily through alcohol recidivism and progressive 
liver disease[3,4]. Continuing efforts to improve long­
term outcome from severe AAH should be directed to 
modify behaviour after hospital discharge.
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in AAH patients they are not associated with higher mortality if actively sought 
and treated. These data will provide clinicians with more confidence to select 
appropriate patients with AAH for treatment with corticosteroids.
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AAH is defined as new onset jaundice (within the previous 3 mo) with serum 
bilirubin > 80 µmol/L and coagulopathy in a heavy drinker [more than 10 units 
alcohol (80 g ethanol) daily in males and 7.5 units (60 g ethanol) in females 
within the previous 4 wk]. Clinically relevant infections were defined as a body 
temperature > 38 ℃ or < 36 ℃ for more than 4 h, ascitic neutrophil count > 
0.25 × 109 L, consolidation on chest radiograph or clinically relevant positive 
microbiological culture of bodily fluid.
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